Clinical Trials Logo

Monoclonal Gammopathy clinical trials

View clinical trials related to Monoclonal Gammopathy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04614558 Recruiting - Clinical trials for Monoclonal Gammopathy

Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Start date: June 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.

NCT ID: NCT03820817 Recruiting - Clinical trials for Waldenstrom Macroglobulinemia

Rifaximin in Patients With Monoclonal Gammopathy

Start date: May 15, 2019
Phase: Phase 1
Study type: Interventional

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

NCT ID: NCT00173264 Recruiting - Tuberculosis Clinical Trials

Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis

Start date: June 2005
Phase: N/A
Study type: Observational

The purpose of this study is to determine whether the monoclonal protein in patients with tuberculosis and monoclonal gammopathy has anti-tuberculous activity, and whether genes coding their monoclonal proteins show characteristic mutations.